GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Natera Inc (NAS:NTRA) » Definitions » Cyclically Adjusted PS Ratio

Natera (Natera) Cyclically Adjusted PS Ratio : 16.00 (As of Jun. 01, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Natera Cyclically Adjusted PS Ratio?

As of today (2024-06-01), Natera's current share price is $106.53. Natera's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $6.66. Natera's Cyclically Adjusted PS Ratio for today is 16.00.

The historical rank and industry rank for Natera's Cyclically Adjusted PS Ratio or its related term are showing as below:

NTRA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 6.12   Med: 10.68   Max: 16.44
Current: 16

During the past years, Natera's highest Cyclically Adjusted PS Ratio was 16.44. The lowest was 6.12. And the median was 10.68.

NTRA's Cyclically Adjusted PS Ratio is ranked worse than
94.74% of 133 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.35 vs NTRA: 16.00

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Natera's adjusted revenue per share data for the three months ended in Mar. 2024 was $3.044. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $6.66 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Natera Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Natera's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Natera Cyclically Adjusted PS Ratio Chart

Natera Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 9.89

Natera Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 7.08 9.89 13.74

Competitive Comparison of Natera's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Natera's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Natera's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Natera's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Natera's Cyclically Adjusted PS Ratio falls into.



Natera Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Natera's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=106.53/6.66
=16.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Natera's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Natera's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.044/131.7762*131.7762
=3.044

Current CPI (Mar. 2024) = 131.7762.

Natera Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.977 100.560 1.280
201409 1.261 100.428 1.655
201412 1.360 99.070 1.809
201503 1.062 99.621 1.405
201506 1.009 100.684 1.321
201509 0.999 100.392 1.311
201512 1.051 99.792 1.388
201603 1.227 100.470 1.609
201606 1.010 101.688 1.309
201609 1.036 101.861 1.340
201612 0.854 101.863 1.105
201703 0.931 102.862 1.193
201706 0.985 103.349 1.256
201709 1.046 104.136 1.324
201712 0.944 104.011 1.196
201803 1.152 105.290 1.442
201806 1.156 106.317 1.433
201809 1.078 106.507 1.334
201812 1.080 105.998 1.343
201903 1.064 107.251 1.307
201906 1.090 108.070 1.329
201909 1.106 108.329 1.345
201912 1.086 108.420 1.320
202003 1.201 108.902 1.453
202006 1.094 108.767 1.325
202009 1.213 109.815 1.456
202012 1.310 109.897 1.571
202103 1.757 111.754 2.072
202106 1.613 114.631 1.854
202109 1.708 115.734 1.945
202112 1.824 117.630 2.043
202203 2.031 121.301 2.206
202206 2.052 125.017 2.163
202209 2.170 125.227 2.283
202212 2.081 125.222 2.190
202303 2.163 127.348 2.238
202306 2.299 128.729 2.353
202309 2.330 129.860 2.364
202312 2.608 129.419 2.655
202403 3.044 131.776 3.044

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Natera  (NAS:NTRA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Natera Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Natera's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Natera (Natera) Business Description

Traded in Other Exchanges
N/A
Address
13011 McCallen Pass, Building A Suite 100, Austin, TX, USA, 78753
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Executives
Michael Burkes Brophy officer: Chief Financial Officer 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Steven Leonard Chapman officer: Chief Operating Officer 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Daniel Rabinowitz officer: CHIEF LEGAL OFFICER C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN TX 78753
Jonathan Sheena director, officer: Chief Technology Officer C/O NATERA, INC., 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Gail Boxer Marcus director 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Rowan E Chapman director 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Matthew Rabinowitz director, officer: Chief Executive Officer C/O NATERA, INC., 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Brinkley Ruth Williams director C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Robert Alan Schueren officer: Chief Operating Officer 7400 PASEO PADRE PARKWAY, FREMONT CA 94555
Roelof Botha director C/O SEQUOIA CAPITAL, 2800 SAND HILL RD, SUITE 101, MENLO PARK CA 94025
Herm Rosenman officer: Chief Financial Officer OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
Todd C Cozzens director ONE FEDERAL STREET, 25TH FLOOR, BOSTON MA 02110
Monica Bertagnolli director C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Roy D. Baynes director C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130